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Quantifying the real life risk profile of inhaled
corticosteroids in COPD by record linkage analysis
Rob W Flynn1, Thomas M MacDonald1, Adrian Hapca1, Isla S MacKenzie1 and Stuart Schembri2*
Abstract
Background: Inhaled corticosteroids (ICS), especially when prescribed in combination with long-acting β2 agonists
have been shown to improve COPD outcomes. Although there is consistent evidence linking ICS with adverse
effects such as pneumonia, the complete risk profile is unclear with conflicting evidence on any association between
ICS and the incidence or worsening of existing diabetes, cataracts and fractures. We investigated this using record
linkage in a Dundee COPD population.
Methods: A record linkage study linking COPD and diabetes datasets with prescription, hospitalisation and mortality
data via a unique Community Health Index (CHI) number. A Cox regression model was used to determine the
association between ICS use and new diabetes or worsening of existing diabetes and hospitalisations for pneumonia,
fractures or cataracts after adjusting for potential confounders. A time dependent analysis of exposure comparing time
on versus off ICS was used to take into account patients changing their exposure status during follow-up and to
prevent immortal time bias.
Results: 4305 subjects (3243 exposed to ICS, total of 17,229 person-years of exposure and 1062 non exposed, with a
follow-up of 4,508 patient-years) were eligible for the study. There were 239 cases of new diabetes (DM) and 265 cases
of worsening DM, 550 admissions for pneumonia, 288 hospitalisations for fracture and 505 cataract related admissions.
The hazard ratio for the association between cumulative ICS and outcomes were 0.70 (0.43-1.12), 0.57 (0.24-1.37), 1.38
(1.09-1.74), 1.08 (0.73-1.59) and 1.42 (1.07-1.88) after multivariate analysis respectively.
Conclusion: The use of ICS in our cohort was not associated with new onset of diabetes, worsening of existing
diabetes or fracture hospitalisation. There was however an association with increased cataracts and pneumonia
hospitalisations.
Keywords: COPD, Inhaled steroids, Diabetes, Pneumonia, Cataract
Background
Chronic obstructive pulmonary disease (COPD) causes
significant morbidity and mortality and is the third leading
cause of death worldwide [1]. The aim of COPD treatment
is to mainly reduce symptoms [2] as no intervention other
than smoking cessation and supplemental oxygen has con-
sistently been shown to improve mortality [3,4].
Inhaled corticosteroids (ICS), especially when prescribed
in combination with long-acting β2 agonists (LABA) im-
prove quality of life (QoL), decrease exacerbations and
hospitalisations, and have been associated with a trend
towards a reduction in all-cause mortality [5]. However,
unlike in asthma where the ICS dose is down titrated to
the lowest possible that ensures symptom control, the
ICS dose utilised in COPD can be quite high; a fre-
quently used regime in the United Kingdom uses 500 μg
fluticasone propionate twice daily [6]. A recent Cochrane
review confirmed that ICS therapy is associated with in-
creased pneumonic events [7]. However the effect of ICS
on other complications such as osteoporotic fractures, on-
set and progression of diabetes, glaucoma and cataracts is
less clear [8-11].
In order to determine which patients should be pre-
scribed ICS, the adverse event profile of ICS must be
properly defined. Knowledge of potential risks is especially
important in situations where a drug is frequently used
outwith the specific group of patients that it should be
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targeted at. This is especially the case with ICS, as for
example in Scotland, the Scottish Medicines Consor-
tium has consistently advised that ICS should not be
used for patients with COPD and a FEV1 > 50% of pre-
dicted [12,13], however, they are nevertheless widely
used in patients outside these strict spirometric param-
eters [14].
We aimed to investigate the association between use
of ICS in COPD and development of incident diabetes
or worsening of prevalent diabetes, and of other adverse
events.
Methods
This was a record-linkage cohort study using databases
from Tayside Scotland. Data from the Tayside Medicines
Monitoring Unit (MEMO) database is held within the
Health Informatics Centre (HIC) [15]. This system collects
data from the Tayside; a compact Scottish geographical
area with a population of over 400,000 people. Health care
for the region is co-ordinated by Tayside Health Board,
which maintains a computerised record of all patients
registered with a general practitioner (GP). In brief, the
MEMO database contains several datasets including all
dispensed community prescriptions, hospital discharge
data, demographic data and biochemistry results. These
data can be linked to disease-specific databases such as
TARDIS (Tayside Allergy and Respiratory Disease Infor-
mation System), DARTS (The Diabetes Audit and Re-
search in Tayside Scotland; now called SCIDC) and
other routine clinical data, all of which are linked by a
Community Health Index (CHI) number that is unique
to each patient.
Data sources
CHI master patient index – this defined the study popula-
tion from which subjects were identified, providing data
on registered GPs and dates that patients got registered,
together with patients' date of birth and date of death.
MEMO prescription dataset – this contains subject
specific data on all prescriptions dispensed from com-
munity pharmacies in Tayside since 1993, including drug
name, formulation, dosage, frequency and duration [15].
This provided data on the principal exposure of interest:
ICS use. Other drug exposures used were other steroid
use and anti-hypertensive medication.
Scottish Morbidity Records 1 (SMR01) – these data are
routinely validated and collated by the Information and
Services Division (ISD) of NHS Scotland and were available
for Tayside from January 1, 1980 [15]. These contained
diagnostic and procedural codes relating to all hospital in-
patient episodes of care using the International Classifica-
tion of Diseases ninth or tenth revisions (ICD-9, ICD-10)
and Office of Population Censuses and Surveys Classifica-
tion of Interventions and Procedures (OCSP4). These data
were used to identify hospital admissions relating to pneu-
monia, fracture and cataract.
TARDIS –This has been described before [16]. GPs in
Tayside refer patients with suspected COPD for screening
spirometry. This is carried out in the GP practices by
COPD nurses after structured training in order to obtain
standardized results. COPD is diagnosed in patients with
a FEV1 < 80% of the predicted value (greatest of pre- and
post-bronchodilator values) and FEV1 /FVC <70%. Patients
with COPD are then invited to participate in TARDIS, a
structured management programme. Patients are seen an-
nually and relevant measures recorded then.
DARTS data – this is a validated population-based clin-
ical information system of patients (>8000) with diabetes
in Tayside. Entries include attendances at hospital diabetes
clinics, dispensed prescriptions for diabetes related medi-
cation and monitoring equipment, hospital discharge
details, community-based mobile diabetic eye screening,
glycosylated haemoglobin (HbA1c) and plasma glucose
results from the regional biochemistry database. Validation
against GP lists has confirmed DARTS to be robust [17].
Study population
Subjects resident in Tayside and registered with a GP be-
tween January 2001 and December 2012. They were cen-
sored if they died or left Tayside during the study period.
Study subjects
Subjects who registered with TARDIS database between
January 2000 and December 2012 and who were 40 years
old or over at diagnosis and who have at least two years
of follow-up time formed the study cohort. The date of
their first diagnosis of COPD (defined as having spirom-
etry showing a FEV1/FVC <0.70) was used as the study
entry date. Patients who had a cancer diagnosis prior to
the diagnosis of COPD were excluded from the study.
Patients who developed cancer during the follow up
time were censored one year prior to the diagnosis of
cancer. For the primary analysis patients with type-1 dia-
betes were excluded.
Exposure
Each dispensed ICS prescription has details of date of
prescription, daily dose, amount and duration. ICS ex-
posure was converted into beclometasone equivalent
doses [6].
Outcomes
The primary outcome was either new cases of type 2
diabetes or worsening of pre-existing diabetes. These are
defined below;
Newly diagnosed diabetes – new diagnosis of type 2
diabetes was recognised using the DARTS database, this
has 95% sensitivity for identifying people with diabetes.
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Worsening of existing diabetic control – defined as either
worsening of HbA1c by >5 mmol/mol or the prescription
of additional hypoglycaemic agents, following the index
visit.
Secondary endpoints – hospitalisations coded as pneu-
monia, fractures and cataracts were obtained from SMR1.
The relevant ICD10 admissions and OPCS4 procedural
codes are listed in Table 1 [18,19].
Covariates
Covariates considered in the analysis consisted of other
factors that could be potential confounders. These were:
(1) Demographics (age, sex, social deprivation score,
smoking status and BMI); (2) Severity of COPD: (FEV1
and ratio of FEV1 /FVC at baseline, MRC dyspnoea
score in the year before the first ICS use; (3) Disease history:
cardiovascular risk defined as either primary or secondary
prevention: primary prevention - hypertension (defined as
on any anti-hypertension drug; treatment) and dyslipidae-
mia (defined as serum total cholesterol >5 mmol/L). Sec-
ondary prevention - myocardial infarction, heart failure,
stroke, peripheral vascular disease (defined as hospitalisa-
tion from the SMR1 database). Renal disease was defined
as having serum creatinine ≥220 μmol/l. For the second-
ary outcomes, a prior history of the outcome “event” at
baseline was included in the model.
Statistical analysis
Baseline characteristics were summarised as mean (SD)/
median (IQR) for continuous variables and number of
subjects (%) for categorical variables. These were com-
pared using t-test for continuous variables and chi-square
test for binary variables. A Cox regression model was used
to explore the relationship between ICS exposure and the
primary and secondary outcomes. Each endpoint was per-
formed as a separate analysis allowing the calculation of
relative risks associated with ICS use for each of the out-
comes. A time dependent analysis of exposure – compar-
ing time “on” versus “off” ICS exposure as judged by
dispensed prescribing – was used to take into account the
fact that patients changed their exposure status during
follow-up and to prevent immortal time bias. The nature
of the association between the exposure and outcome was
incorporated into the time dependent model following
that thought most biologically plausible: for cataract
and osteoporosis this was cumulative steroid exposure;
for pneumonia was current exposure; whilst for diabetes
both cumulative and current exposure were modelled as
there is no clear mechanism.
Both univariate and multivariate analyses were carried
out. The multivariate analyses included all covariates
thought to be potential confounders in an attempt to es-
tablish the true treatment effect. Variables included in
the statistical models were potential predictors of the
outcome events. Other covariates were evaluated once at
the start of the follow up period. For the pneumonia
outcome the population attributable risk was calculated
by multiplying (hazard ratio-1)/hazard ratio by the prob-
ability of disease given exposure.
The exposed cohort was followed up from the date of
first exposure to ICS. Non-ICS exposed patients were
followed up from a randomly generated surrogate date
of first “exposure” generated using a frequency-matched
calendar year date of exposure. All statistical analyses
were carried out using SAS (version 9.2).
There were very few missing data in the record linked
data: (1.1% deprivation score, 4.4% BMI, 4.6% dyspnoea
score). Where covariates did have missing values a
complete case analysis performed. To establish if there
were any relevant interactions in the multivariate ana-
lyses, two-way interactions terms were modelled in-
corporating ICS exposure and other key covariates of
interest.
Sensitivity analyses
A number of sensitivity analyses were carried out to test
the robustness of the finding. First we used an inception
cohort – consisting of only those patients naive to ICS
at the start of follow-up.
Propensity score matching was used to explore pos-
sible confounding by indication that was not adequately
controlled for by the Cox model. In view of data showing
that the effect of ICS on pneumonia is no longer evident
6 months after drug cessation [20], analyses were also run
using an extended screening period of 6-months to test
the stability of the models generated and to see if there
was any evidence of a carryover effect. The primary ana-
lysis considered any dose of ICS, versus none. As sensitiv-
ity analysis we also attempted to establish if there was a
dose-response between exposure and outcome at zero,
low, medium and high ICS doses. To standardise different
doses of ICS we mapped potency as budesonide = becla-
metasone =50% fluticasone (i.e. 1mcg budesonide =1mcg
beclometasone =0.5mcg fluticasone) [6]. This approach
allowed the dose response of the different ICS products to
be compared. Similarly this standardisation was also used
to allow comparison of the different steroids, to see if it
Table 1 Coding systems and specific codes used to identify
study endpoints
Outcome Coding system and codes used
Pneumonia ICD10: J12, J15, J16, J17, J18
Fractures ICD10: S02, S12, S22, S32, S42, S52, S62, S72, S82, S92
Cataracts OSCP4: C71, C72, C73, C74, C75
ICD 10 code:H25
ICD10 - International Statistical Classification of Diseases 10th revision.
OSCP4 - Office of Population Censuses and Surveys Classification of Surgical
Operations 4th revision.
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was possible to detect a difference between outcome
and the type of steroid used (i.e. fluticasone vs “other” –
beclometasone, budesonide etc).
To assess the impact of “other” (non-inhaled) steroid
use, a sensitivity analysis was also conducted which
stratified the cohort by extent of other steroid use. Finally
we also repeated analyses using a fully time dependent
analysis starting from point of diagnosis on TARDIS for all
patients rather than the date of first exposure (or “surrogate
date” of exposure as described).
Results
We identified 4,305 subjects as being eligible for the study
cohort. Figure 1 details the number of patient available on
the TARDIS database and details on excluded patients.
3,243 were exposed to ICS for a total of 17,229 person-
years of exposure, and 1,062 were unexposed with a
follow-up of 4,508 years. A comparison of the baseline
characteristics of the exposed and unexposed cohorts is
shown in Table 2. Fluticasone was responsible for 67.7%
of the ICS prescription exposure and beclometasone for
20.5%. The remaining ICS prescriptions (11.8%) were for
budesonide. There were 239 cases of newly diagnosed and
265 cases of worsening of existing diabetes. For the sec-
ondary outcomes there were 550 admissions for pneumo-
nia, 288 hospitalisations for fracture and 505 cataract
related admissions. The number of events by exposure
group and exposure time is shown in Table 3. This
shows the nature of the risk for the two components of
the primary endpoint to be quite different, with the new
onset diabetes being uncommon across a large number
of patients, whilst the worsening of diabetes outcome
was extremely common across a small number of pa-
tients. For this reason these two endpoints were treated
separately for the remaining analyses.
The results of the multivariate analyses are shown in
Table 4. These show that there was no association be-
tween ICS use and either onset of new cases of diabetes
or cases of worsening of existing diabetes. This was con-
sistent across the whole range of sensitivity analyses that
were run. For the secondary endpoints a consistent associ-
ation was found between ICS and increased risk of both
hospital admissions for pneumonia and cataract, but not
fracture. The sensitivity analyses using models that incor-
porated various drug exposure screening periods found
evidence of a carryover effect for the pneumonia outcome.
This implies that the association between ICS use and
hospitalisation for pneumonia continues to be present for
some time after the ICS use has ceased (Tables 4 and 5).
The population attributable risk associated with the use of
ICS is an extra 7.4 pneumonia hospitalisation per 1,000
person years of exposure, with the results that of the 550
Figure 1 CONSORT diagram showing derivation of study cohort.
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observed pneumonia hospitalisation in our study cohort
131 (23.8%) could be attributed to use of ICS. A statisti-
cally significant interaction between age and sex was
found for the pneumonia outcome only; other interaction
terms were not significant. Table 5 shows the association
between fluticasone alone and other ICS with outcomes.
This shows that there were no differences between steroid
groups and incidence of diabetes or fractures however
there are increased pneumonic and cataract hospitalisa-
tions in the patients treated with fluticasone. Analysing
only the group of patients on ICS showed that flutica-
sone had a significantly increased risk of pneumonia
hospitalisation (HRs no carryover 1.39 (1.06-1.82), 180 day
carryover 1.43 (1.14-1.78)) when compared with individuals
on other ICS.
The extent of steroid use via all routes is shown in
Table 6. This shows that there was widespread use of
steroids administered by other routes. Indeed the majority
of patient received greater exposure to oral than inhaled
steroid. Use of rectal steroids was not common and the
true extent to which systemic absorption of topical ste-
roids is an issue is hard to assess. However the addition of
oral steroid exposure to the models had little impact on
the point estimates of the hazard ratios for the primary
Table 3 Number of events and year of follow-up for each of the study endpoints
Event ICS exposed (n = 3243) ICS unexposed (n = 1062)
n events Person-years
follow-up*
Event rate
(per 1000 person years)
n event Person-years
follow-up
Event rate
(per 1000 person years)
New onset diabetes
(n at risk =3,941)
186 16,634 11.2 53 4,285 12.4
Worsening of existing diabetes
(n at risk =364)
194 595 326.1 71 223 318.4
Hospitalisation for pneumonia 476 17,795 26.8 74 4,833 15.3
Hospitalisation for fracture 234 18,097 12.9 54 4,822 11.2
Cataract 411 17,314 23.7 94 4,581 20.5
*”person years follow-up” is the number of years exposure / non-exposure during which subjects were at risk of suffering the event of interest. This varies
depending on the number of subjects in the cohort and the number / timing of any events that occurred.
Table 2 Comparison of the baseline characteristics of the ICS exposed and unexposed cohorts
Continuous variables ICS exposed ICS un-exposed p value#
(n = 3243) (n = 1062)
Mean age (years) 65.5 67.2 < 0.0001
Mean BMI (kg/m2) 26.3 26.6 0.1772
Smoking (pack years) 34.7 39.0 < 0.0001
Social deprivation (Scottish index of multiple deprivation; 1 =most deprived, 5 =most affluent) 2.31 2.29 0.5972
Dyspnoea score (1 = least breathless, 5 =most breathless) 2.57 2.19 < 0.0001
Gender (female) 51.9% 49.5% 0.1693
Primary CV prevention (hypertension, dyslipidaemia) 73.4% 79.0% 0.0003
Secondary CV prevention (myocardial infarction, heart failure, stroke, PVD) 11.3% 15.6% 0.0002
Renal diseases history 2.9% 2.5% 0.4692
Diabetes history 8.0% 9.8% 0.0711
Pneumonia history 5.4% 3.8% 0.0375
Fracture history 5.7% 5.8% 0.8413
Cataract history 10.3% 10.9% 0.5840
Oral steroids prescription history 58.9% 30.0% < 0.0001
Rectal steroids prescription history 11.8% 10.4% 0.1971
Topical steroids prescription history 61.1% 59.8% 0.4540
FEV1 baseline (Litres) 1.63 (0.65) 1.82 (0.63) < 0.0001
Percent predicted FEV1
* 74.9 (23.3) 85.0 (20.8) < 0.0001
FEV1 /FVC ratio 55.1 (10.9) 59.8 (8.6) < 0.0001
*“Percentage predicted” is baseline FEV1 expressed as percentage of predicted FEV1.
#t-test for continuous variables and chi-square test for binary variables.
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and secondary endpoints. The other sensitivity analyses
yielded results that had no impact of the main finding of
this study. The inception cohort analyses resulted in a suf-
ficiently small cohort that results tended to be non-
significant. The propensity score analyses showed nothing
to suggest that they offered any additional adjustment for
confounding. Similarly the other sensitivity analyses under-
taken showed the study findings to be robust.
Discussion
Our results show that the use of ICS in our cohort was
not associated with new onset of diabetes or worsening
Table 4 Association between inhaled steroids and outcomes
Outcome Univariate
hazard ratio
Multivariate
hazard ratio
Other variables contained in adjusted multivariate model
(95% CI) (95% CI)
Primary endpoints
New onset diabetes
Any exposure 0.88 (0.68-1.14) 0.94 (0.71-1.25) Age*, sex, deprivation, history ICS, history oral steroids*, smoking, BMI*, primary CV
history*, secondary CV history*, renal dysfunction, COPD severity
Cumulative exposure 0.71 (0.46-1.10) 0.70 (0.43-1.12) Age*, sex, deprivation, history ICS, history oral steroid*, smoking, BMI*, primary CV
history*, secondary CV history, renal dysfunction, COPD severity
Worsening of existing diabetes
Current exposure 0.94 (0.73-1.21) 0.91 (0.73-1.21) Age*, sex, deprivation, previous ICS, history of oral steroid use, smoking, BMI, primary CV
history, secondary CV history, renal dysfunction, COPD severity*
Cumulative exposure 0.57 (0.25-1.30) 0.57 (0.24-1.37) Age*, sex, deprivation, previous ICS, history of oral steroid, smoking, BMI, primary CV
history, secondary CV history, renal dysfunction, COPD severity*
Secondary endpoints
Hospitalisation for pneumonia
Current exposure no
carryover
1.27 (1.07-1.50) 1.13 (0.94-1.36) Age*, sex, deprivation*, previous ICS, history of oral steroid, smoking*, BMI*, primary CV
history*, secondary CV history*, renal dysfunction, COPD severity*, history of diabetes*,
history of pneumonia admission*
Current exposure with
180-day carryover
1.58 (1.29-1.93) 1.38 (1.09-1.74)
Hospitalisation for fracture
Cumulative exposure 1.06 (0.75-1.51) 1.08 (0.75-1.51) Age*, sex*, deprivation, previous ICS, history of oral steroid, smoking, BMI*, primary CV
history, secondary CV history, renal dysfunction, COPD severity, history of diabetes,
history of fracture admission*
Cataract related outcome
Cumulative exposure 1.43 (1.11-1.83) 1.42 (1.07-1.88) Age*, sex, deprivation, previous ICS, history of oral steroid, smoking*, BMI, primary CV
history*, secondary CV history, renal dysfunction, COPD severity*, history of diabetes*,
history of cataract related admission
*Shows variables that were found to be significant in the model.
Abbreviations: CI confidence interval, ICS inhaled corticosteroids, BMI body mass index, CV cardiovascular, COPD chronic obstructive pulmonary disease.
“COPD severity” is the actual FEV1 and a percentage of predicted FEV1.
Table 5 Comparison of effect of fluticasone and “other ICS” on outcomes
Outcome Multivariate hazard ratio
(95% CI)
No ICS Other ICS Fluticasone
Primary endpoints
New case diabetes 1.00 0.98 (0.69-1.39) 0.82 (0.58-1.15)
Worsening of existing diabetes 1.00 1.01 (0.72-1.41) 0.84 (0.60-1.17)
Secondary endpoints
Hospitalisation for pneumonia
No carryover 1.00 0.88 (0.68-1.14) 1.23 (1.01-1.51)
180-day carryover 1.00 1.05 (0.79-1.39) 1.50 (1.17-1.91)
Hospitalisation for fracture 1.00 1.08 (0.72-1.60) 1.10 (0.57-2.10)
Cataract related outcome 1.00 1.34 (0.99-1.82) 2.24 (1.40-3.60)
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of existing diabetes. Although systemic corticosteroids
have a well recognised role in increasing diabetes risk
[21], the impact of ICS is less well characterised and our
study adds to the body of evidence in this field. Initial
studies did not show an association between ICS use
and diabetes [22,23], however a large population based
study of 388,584 patients with respiratory disease (not
just COPD) showed that ICS treatment was associated
with a 34% increased risk of new onset diabetes (defined
as initiation of an oral hypoglycaemic agent), with those
on the highest ICS dose having the greatest risk [11].
More recently, a retrospective study of administrative
claims data from the Australian Government Department
of Veterans’Affairs of more than 18,000 patients with dia-
betes, found there to be an increased risk of diabetes-
related hospitalisations with the use of high-dose ICS [24].
Following this observational data, O’Byrne and colleagues
examined double-blind, placebo-controlled, trials in pa-
tients ≥4 years of age with asthma or COPD involving
budesonide or fluticasone to a lesser extent and did not
find an association between inhaled corticosteroid treat-
ment and increased risk of new onset diabetes mellitus or
hyperglycaemia [25]. This is consistent with our findings
and suggests that any effect of ICS on diabetes in
COPD patients, if present at all, is unlikely to be clinic-
ally significant.
The relationship between ICS and pneumonia risk was
first noted in TORCH with participants receiving ICS
treatment having a two-fold higher rate of pneumonia
when compared with those in the placebo arm [5].
These events were often diagnosed and managed in pri-
mary care, our results show that ICS use was also associ-
ated with hospitalisation for pneumonia. It has been
suggested that ICS type may influence the risk of pneu-
monia, with a recent Cochrane review and studies such
as PATHOS suggesting that fluticasone carries a higher
risk than others such as budesonide; this difference is
also seen in our study [7,26]. Fluticasone’s increased im-
munosuppressant potency (10-fold higher than that of
budesonide with regard to ex vivo inhibition of human
alveolar macrophage innate immune response to bacter-
ial triggers) [27] could potentially explain these findings.
As with other datasets we have shown that ICS use is
associated with cataract surgery but not hospitalisation
for fractures suggesting that there is no clinically signifi-
cant association with osteoporosis [9,28]. Indeed a recent
Cochrane review reported that ICS were not associated
with an effect on fractures and bone mineral density [29]
A previously unreported association was that fluticasone
was more strongly associated with cataract surgery than
other ICS, it is unclear why this may be the case however
dose effect may be one explanation.
In order to justify prescribing ICS one must have data
on the risk/benefit balance hence understanding the ad-
verse effects of ICS is key. Although ICS have been shown
to improve QoL, decrease exacerbations and hospitalisa-
tions and possibly improve mortality, evidence of benefit
is limited to individuals with FEV1 < 70% predicted [30].
Studies that solely recruited patients with milder disease
did not show similarly improved outcomes [31] however
several studies have shown that over half of ICS use in
daily practice falls outwith strict spirometric parameters
included in COPD guidelines [32].
The strengths of this study are that data were collected
in routine care with minimal exclusions: this increases the
likelihood that the results will be applicable to other popu-
lations. Another strength is that all COPD diagnoses were
validated using spirometric data, to our knowledge this
is the first observational study on the effects of ICS and
diabetes in COPD that has done this. Despite data being
collected prospectively according to predefined criteria,
follow-up data are observational and therefore prone to
the weaknesses of this type of study. Though we attempted
to limit bias by adjusting for other potential confounders,
bias due to unrecorded factors may remain.
Conclusions
ICS exposure in our cohort was not associated with new
onset of diabetes, worsening of existing diabetes or frac-
ture hospitalisation. There was however an association
with increased cataracts and pneumonia hospitalisations.
Knowing the adverse effect profile of ICS is especially im-
portant as they are often used in patients with no proven
evidence of benefit.
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